



PRIOR AUTHORIZATION REQUEST

Ebglyss

Patient Information:

| | |
|-------------------|--|
| Name: | |
| Member ID: | |
| Address: | |
| City, State, Zip: | |
| Date of Birth: | |

Prescriber Information:

| | |
|-------------------|--|
| Name: | |
| NPI: | |
| Phone Number: | |
| Fax Number: | |
| Address: | |
| City, State, Zip: | |

Requested Medication

| | |
|-----------------------------|--|
| Rx Name: | |
| Rx Strength: | |
| Rx Quantity: | |
| Rx Frequency: | |
| Rx Route of Administration: | |
| Diagnosis and ICD Code: | |

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1 Is the request an INITIAL or CONTINUATION of therapy?

☐ Initial (If checked, go to 7)

☐ Continuation (If checked, go to 2)

2 Is the patient currently receiving the requested medication?

Yes No

[If no, skip to question 7.]

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

| | | | |
|----|---|-----|----|
| 3 | <p>Has the patient been receiving medication samples of Ebglyss? [If yes, skip to question 7.]</p> | Yes | No |
| 4 | <p>Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]</p> | Yes | No |
| 5 | <p>Will the patient be concurrently receiving the requested medication in combination with any monoclonal antibody, anti-IL4, anti-IL5, or TSLP inhibitor such as Adbry, Cinqair, Dupixent, Fasenra, Nemluvio, Nucala, Tezspire or Xolair? [If yes, no further questions.]</p> | Yes | No |
| 6 | <p>Has the patient been taking the requested medication for at least 4 months and has experienced a clinically significant benefit from the medication, as documented by the prescriber? ACTION REQUIRED: Submit supporting documentation. [Note: Atopic dermatitis – Examples of a response to the requested medication are marked improvements in erythema, induration/papulation/edema, excoriations, and lichenification; reduced pruritus; decreased requirement for other topical or systemic therapies; reduced body surface area affected with atopic dermatitis; or other responses observed] [No further questions.]</p> | Yes | No |
| 7 | <p>What is the indication or diagnosis? <input type="checkbox"/> Atopic dermatitis (If checked, go to 8) <input type="checkbox"/> Other (If checked, no further questions)</p> | | |
| 8 | <p>Is the patient greater than or equal to 12 years of age?</p> | Yes | No |
| 9 | <p>What is the weight of the patient? <input type="checkbox"/> Less than 40 kg (If checked, no further questions) <input type="checkbox"/> More than or equal to 40 kg (If checked, go to 10)</p> | | |
| 10 | <p>Will the patient be concurrently receiving the requested medication in combination with</p> | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025

PRIOR AUTHORIZATION REQUEST

any monoclonal antibody, anti-IL4, anti-IL5, or TSLP inhibitor such as Adbry, Cinqair, Dupixent, Fasenra, Nemluvio, Nucala, Tezspire or Xolair?

[If yes, no further questions.]

- | | | | |
|----|---|-----|----|
| 11 | <p>Has the patient undergone treatment with any immunosuppressive medications within the last 4 weeks (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-γ, Janus kinase inhibitors, azathioprine, methotrexate, etc.)?</p> <p>[If yes, no further questions.]</p> | Yes | No |
| 12 | <p>Does the patient have a documented diagnosis of moderate to severe atopic dermatitis?</p> <p>[If no, no further questions.]</p> | Yes | No |
| 13 | <p>Does the prescribed dosing exceed FDA approved indication?</p> <p>[If yes, no further questions.]</p> | Yes | No |
| 14 | <p>Has documentation been provided to confirm that the patient has an IGA score of greater than or equal to 3 and an EASI score of greater than or equal to 16? ACTION REQUIRED: Submit supporting documentation.</p> <p>[If no, no further questions.]</p> | Yes | No |
| 15 | <p>Does the patient have atopic dermatitis involvement estimated to be greater than or equal to 10% of the body surface area (BSA) according to the prescriber? ACTION REQUIRED: Submit supporting documentation.</p> <p>[If yes, go to question 17.]</p> | Yes | No |
| 16 | <p>Does the patient have atopic dermatitis affecting the following areas: hands, face, feet, eyes/eyelids, neck, scalp, skin folds, and/or genitalia?</p> <p>[If no, no further questions.]</p> | Yes | No |
| 17 | <p>Has the patient tried at least TWO medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroids? ACTION REQUIRED: Submit supporting documentation.</p> <p>[If no, no further questions.]</p> | Yes | No |
| 18 | <p>Has the patient tried tacrolimus ointment? ACTION REQUIRED: Submit supporting documentation.</p> <p>[If no, no further questions.]</p> | Yes | No |
| 19 | <p>Were the topical corticosteroids and tacrolimus ointment applied daily for at least 28 consecutive days?</p> <p>[If no, no further questions.]</p> | Yes | No |

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025



PRIOR AUTHORIZATION REQUEST

| | | | |
|----|---|-----|----|
| 20 | Was inadequate efficacy demonstrated with the topical therapies, according to the prescriber? [If no, no further questions.] | Yes | No |
| 21 | Has the patient tried Zoryve? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.] | Yes | No |
| 22 | Was Zoryve applied daily for at least 56 consecutive days? [If no, no further questions.] | Yes | No |
| 23 | Was inadequate efficacy demonstrated with Zoryve, according to the prescriber? [If no, no further questions.] | Yes | No |
| 24 | Is the requested medication being prescribed by or in consultation with an allergist, immunologist, or dermatologist? | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025